154 related articles for article (PubMed ID: 35560035)
1. Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards.
Love TM; Anaya DA; Prime MS; Ardolino L; Ekinci O
PLoS One; 2022; 17(5):e0268477. PubMed ID: 35560035
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
[TBL] [Abstract][Full Text] [Related]
3. Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G; Canfora M; Terrenato I; Agnoletto C; Agustoni F; Amoroso L; Baldassarre G; Curigliano G; Delmonte A; De Luca A; Fiorentino M; Gregorc V; Ibrahim T; Lazzari C; Mastronuzzi A; Pronzato P; Santoro A; Scambia G; Tommasi S; Vingiani A; Giacomini P; De Maria R
J Exp Clin Cancer Res; 2022 Oct; 41(1):305. PubMed ID: 36245005
[TBL] [Abstract][Full Text] [Related]
4. Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.
Naito Y; Sunami K; Kage H; Komine K; Amano T; Imai M; Koyama T; Ennishi D; Kanai M; Kenmotsu H; Maeda T; Morita S; Sakai D; Watanabe K; Shirota H; Kinoshita I; Yoshioka M; Mamesaya N; Ito M; Kohsaka S; Saigusa Y; Yamamoto K; Hirata M; Tsuchihara K; Yoshino T
JAMA Netw Open; 2022 Dec; 5(12):e2245081. PubMed ID: 36469316
[TBL] [Abstract][Full Text] [Related]
5. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
6. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
Willemsen AECAB; Krausz S; Ligtenberg MJL; Grünberg K; Groen HJM; Voest EE; Cuppen EPJG; van Laarhoven HWM; van Herpen CML
Br J Cancer; 2019 Jul; 121(1):34-36. PubMed ID: 31130724
[TBL] [Abstract][Full Text] [Related]
7. Molecular Tumor Boards: current practice and future needs.
van der Velden DL; van Herpen CML; van Laarhoven HWM; Smit EF; Groen HJM; Willems SM; Nederlof PM; Langenberg MHG; Cuppen E; Sleijfer S; Steeghs N; Voest EE
Ann Oncol; 2017 Dec; 28(12):3070-3075. PubMed ID: 29045504
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.
Engelhardt M; Ihorst G; Schumacher M; Rassner M; Gengenbach L; Möller M; Shoumariyeh K; Neubauer J; Farthmann J; Herget G; Wäsch R
BMC Cancer; 2021 Feb; 21(1):173. PubMed ID: 33596881
[TBL] [Abstract][Full Text] [Related]
9. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide.
Rieke DT; Lamping M; Schuh M; Le Tourneau C; Basté N; Burkard ME; Metzeler KH; Leyvraz S; Keilholz U
JCO Precis Oncol; 2018 Nov; 2():1-14. PubMed ID: 35135153
[TBL] [Abstract][Full Text] [Related]
11. Software-Tool Support for Collaborative, Virtual, Multi-Site Molecular Tumor Boards.
Schapranow MP; Borchert F; Bougatf N; Hund H; Eils R
SN Comput Sci; 2023; 4(4):358. PubMed ID: 37131499
[TBL] [Abstract][Full Text] [Related]
12. Clinician Perspectives Regarding the Impact of Information Technology on Multidisciplinary Tumor Boards: A National Comprehensive Cancer Network Survey.
Arafat W; Fu P; Wagner AJ; Osterman T; Martin DB; Sugalski J; Heinrichs T; Racz J; Tevaarwerk AJ
JCO Clin Cancer Inform; 2023 Sep; 7():e2300056. PubMed ID: 37944060
[TBL] [Abstract][Full Text] [Related]
13. Genomic expertise in action: molecular tumour boards and decision-making in precision oncology.
Bourret P; Cambrosio A
Sociol Health Illn; 2019 Nov; 41(8):1568-1584. PubMed ID: 31197873
[TBL] [Abstract][Full Text] [Related]
14. Implementing multidisciplinary tumor boards in oncology: a narrative review.
Mano MS; Çitaku FT; Barach P
Future Oncol; 2022 Jan; 18(3):375-384. PubMed ID: 34787482
[TBL] [Abstract][Full Text] [Related]
15. Quality of leadership in multidisciplinary cancer tumor boards: development and evaluation of a leadership assessment instrument (ATLAS).
Jalil R; Soukup T; Akhter W; Sevdalis N; Green JSA
World J Urol; 2018 Jul; 36(7):1031-1038. PubMed ID: 29502300
[TBL] [Abstract][Full Text] [Related]
16. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
Mathew A; Davis S; Boby JM; R I A; Suryavanshi M; Dawood SS; Panda PK; Nag SM; Das A; Rohatgi N; Popat S; Shah RNH; Thampy C; Parikh AR; Yadav S; Mehta P; Singh R; Mukherji D; Shilpakar R; Mullapally SK; Sirohi B
JCO Glob Oncol; 2024 Mar; 10():e2300330. PubMed ID: 38484196
[TBL] [Abstract][Full Text] [Related]
17. Extending cBioPortal for Therapy Recommendation Documentation in Molecular Tumor Boards: Development and Usability Study.
Renner C; Reimer N; Christoph J; Busch H; Metzger P; Boerries M; Ustjanzew A; Boehm D; Unberath P
JMIR Med Inform; 2023 Dec; 11():e50017. PubMed ID: 38079196
[TBL] [Abstract][Full Text] [Related]
18. Precision Oncology Core Data Model to Support Clinical Genomics Decision Making.
Botsis T; Murray JC; Ghanem P; Balan A; Kernagis A; Hardart K; He T; Spiker J; Kreimeyer K; Tao J; Baras AS; Yegnasubramanian S; Canzoniero J; Anagnostou V;
JCO Clin Cancer Inform; 2023 Apr; 7():e2200108. PubMed ID: 37040583
[TBL] [Abstract][Full Text] [Related]
19. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients.
Lamb BW; Green JS; Benn J; Brown KF; Vincent CA; Sevdalis N
J Am Coll Surg; 2013 Sep; 217(3):412-20. PubMed ID: 23891067
[TBL] [Abstract][Full Text] [Related]
20. Practice and Impact of Multidisciplinary Tumor Boards on Patient Management: A Prospective Study.
Charara RN; Kreidieh FY; Farhat RA; Al-Feghali KA; Khoury KE; Haydar A; Nassar L; Berjawi G; Shamseddine A; El Saghir NS
J Glob Oncol; 2017 Jun; 3(3):242-249. PubMed ID: 28717766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
